SCHEMBL20141232

SCHEMBL20141232

Cc1cc(C)c(C(=O)OC(C)(C)C)c(C)c1NC1CCN(c2cnccn2)CC1

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.52
KDM4E B2RXH2 7/20 0.50
TP53 P04637 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MTOR P42345 2/20 0.41
RPTOR Q8N122 2/20 0.41
MLST8 Q9BVC4 2/20 0.41
RXFP1 Q9HBX9 1/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
ATM Q13315 1/20 0.39
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20141229 0.87 GPR119 (0.52) GPR119KDM4EMTORRPTORMLST8
SCHEMBL20140970 0.86 KDM4E (0.55) GPR119KDM4ETP53L3MBTL1MTOR
SCHEMBL21360378 0.85 KDM4E (0.54) GPR119KDM4ETP53L3MBTL1MTOR
Hydrochloric Acid SCHEMBL20140989 0.84 KDM4E (0.53) GPR119KDM4ETP53L3MBTL1MTOR
SCHEMBL20141276 0.83 MTOR (0.54) GPR119KDM4EMTORRPTORMLST8
SCHEMBL20141336 0.82 MTOR (0.54) MTORRPTORMLST8
SCHEMBL20141057 0.79 ALDH1A1 (0.41) GPR119KDM4ETP53L3MBTL1MTOR
SCHEMBL22187892 0.77 MTOR (0.53) GPR119KDM4EMTORRPTORMLST8
SCHEMBL22187869 0.77 MTOR (0.60) KDM4ETP53L3MBTL1MTORRPTOR
SCHEMBL20140922 0.76 MTOR (0.60) GPR119KDM4EMTORRPTORMLST8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10844013-B2 Phenyl amino piperidine mTORC inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2020-11-24 US disclosed
US-10844013-B2 Phenyl amino piperidine mTORC inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2020-11-24 US disclosed
US-20200207716-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2020-07-02 US disclosed
US-20200207716-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2020-07-02 US disclosed
EP-3538091-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF Navitor Pharmaceuticals, Inc. (US) 2019-09-18 EP disclosed
US-10414727-B2 Phenyl amino piperidine mTORC inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2019-09-17 US disclosed
US-10414727-B2 Phenyl amino piperidine mTORC inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2019-09-17 US disclosed
WO-2018089499-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed
US-20180127370-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10844013-B2 Phenyl amino piperidine mTORC inhibitors and uses thereof MTOR, RICTOR, RPTOR GPR119 2282/4885KDM4E 253/4885TP53 935/4885
US-10414727-B2 Phenyl amino piperidine mTORC inhibitors and uses thereof MTOR, RICTOR, RPTOR GPR119 2282/4885KDM4E 253/4885TP53 935/4885
US-20180127370-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF MTOR, RICTOR, RPTOR GPR119 2282/4885KDM4E 253/4885TP53 935/4885
US-20200207716-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF MTOR, RICTOR, RPTOR GPR119 2282/4885KDM4E 253/4885TP53 935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.